|
|
|
| Expression and clinical significance of chemokine CXCL14 in nasopharyngeal carcinoma |
1.Department of Otorhinolaryngology, the Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People’s Hospital ,Wenzhou, 325000; 2.Department of Pathology, the Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou People’s Hospital, Wenzhou, 325000; 3.Department of Otorhinolaryngology, the No.118 Hospital of PLA, Wenzhou, 325000
|
|
| Cite this article: |
|
ZHOU Yifei1,WANG Zhaoliang1,ZHANG Yu1, et al. Expression and clinical significance of chemokine CXCL14 in nasopharyngeal carcinoma[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(11): 814-.
|
|
|
Abstract Objective: To investigate the expression of chemokine CXCLl4 and its clinical significance in nasopharyngeal cancer (NPC). Methods: Thirty patients with NPC were selected as the disease group and another 30 cases with nasopharyngitis as control group. Biopsy with nasopharyngeal tissue was performed. The CXCLl4 expression was detected with real-time fluorescence quantitative PCR and immunohistochemistry. Results: The CXCLl4 expression with NPC tissues in mRNA and protein levels declined compared with the control group (P<0.001). Correlative analysis showed the dow-nregulation of CXCLl4 expression in protein levels with NPC tissues was associated with T classification of tumor (P=0.001), lymph node metastasis (P=0.028) and the clinical stage (P=0.001). Conclusion: It is possible that CXCLl4 plays a role in the development and progression of NPC.
|
|
Received: 09 August 2015
|
| |
|
|
|
[1] 徐国镇, 唐平章, 罗京伟. 加强以放射治疗为主的鼻咽癌综合治疗研究[J]. 中华耳鼻咽喉头颈外科杂志, 2012, 47 (3): 177-179.
[2] 朱鲁程, 邹长林. EGFR单抗联合放疗与单纯放疗在中晚期鼻咽癌中疗效比较的Meta分析[J]. 温州医学院学报,2013, 43(9): 626-629.
[3] Hara T, Tanegashima K. Pleiotropic functions of the CXCtype chemokine CXCL14 in mammals [J]. Biochem, 2012,151(5): 469-476.
[4] Wong MM, Fish EN. Chemokines: attractive mediators of the immune response[J]. Semin Immunol, 2003, 15(1): 5-14.
[5] Hromas R, Broxmeyer HE, Kim C, et a1. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells[J]. Bioehem Biophys Res Commun, 1999, 255(3): 703-706.
[6] Tanegashima K, Suzuki K, Nakayama Y, et al. CXCL14 is anatural inhibitor of the CXCL12-CXCR4 signaling axis[J]. FEBS Lett, 2013, 587(12): 1731-1735.
[7] Frederick MJ, Henderson Y, Xu X, et a1. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue[J]. Am J Pathol, 2000, 156(6): 1937-1950.
[8] Kuang H, Chen Q, Fan X, et al. CXCL14 inhibits trophoblast outgrowthvia a paracrine autocrine manner during early pregnancy in mice[J]. J Cell Physiol, 2009, 221(2): 448-457.
[9] Wikman H, Westphal L, Schmid F, et al. Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients[J]. Oncotarget, 2014, 5(10): 3076-3087.
[10] Hu C, Lin F, Zhu G, et a1. Abnormal hypermethylation of promoter region downregulates chemokine CXC ligand 14 expression in gastric cancer[J]. Int J Oncol, 2013, 43(5): 1487-1494.
[11] Song EY, Shurin MR, Tourkova IL, et al. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells[J]. Cancer Res, 2010, 70(11): 4394-4401.
[12] Cao B, Yang Y, Pan Y, et a1. Epigenetie silencing of CXCLl4 inducedeolorectal cancer migration and invasion[J]. Discov Med, 2013, 16(88): 137-147.
[13] Zeng J, Yang X, Cheng L, et a1. Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection[J]. J Transl Med, 2013, 11(1):6-21.
[14] Lin K, Zou R, Lin F, et a1. Expression and effect of CXCL14 in colorectal carcinoma[J]. Mol Med Rep, 2014, 10(3): 1561-1568.
[15] Ozawa S, Kato Y, Komori R, et al. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells[J]. Biochem Biophys Res Commun, 2006, 348(2):406-412
[16] Ito S, Ozawa S, Ikoma T, et al. Expresssion of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vito[J]. Biomed Res, 2010, 31(3): 199-206.
[17] Ozawa S, Kato Y, Kubota E, et al. BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse[J]. Biomed Res, 2009, 30(5):315-318.
[18] Miyamoto C, Maehata Y, Motohashi K, et al. Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma[J]. Biomed Res, 2014, 35(6): 381-388.
|
|
|
|
